A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models.
about
Pseudomonas aeruginosa ventilator-associated pneumonia managementProtective Efficacy of the Trivalent Pseudomonas aeruginosa Vaccine Candidate PcrV-OprI-Hcp1 in Murine Pneumonia and Burn Models.Synthesis and structure-activity relationships of novel phenoxyacetamide inhibitors of the Pseudomonas aeruginosa type III secretion system (T3SS).High Throughput Combinatorial Formatting of PcrV Nanobodies for Efficient Potency ImprovementGenetic engineering of Francisella tularensis LVS for use as a novel live vaccine platform against Pseudomonas aeruginosa infections.Innate Immune Signaling Activated by MDR Bacteria in the AirwayPseudomonas aeruginosa Bacteremic Patients Exhibit Nonprotective Antibody Titers Against Therapeutic Antibody Targets PcrV and Psl Exopolysaccharide.Draft Genome Sequence of a Pseudomonas aeruginosa Strain Able To Decompose N,N-Dimethyl Formamide.Inhibition of Pseudomonas aeruginosa ExsA DNA-Binding Activity by N-Hydroxybenzimidazoles.HigB of Pseudomonas aeruginosa Enhances Killing of Phagocytes by Up-Regulating the Type III Secretion System in Ciprofloxacin Induced Persister Cells.The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance.Pediatric Multiple Organ Dysfunction Syndrome: Promising Therapies.Considerations and caveats in anti-virulence drug development.A multifunctional bispecific antibody protects against Pseudomonas aeruginosa.Pharmacological Targeting of the Host-Pathogen Interaction: Alternatives to Classical Antibiotics to Combat Drug-Resistant Superbugs.Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance.Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach.Impact of Type III Secretion Effectors and of Phenoxyacetamide Inhibitors of Type III Secretion on Abscess Formation in a Mouse Model of Pseudomonas aeruginosa Infection.Nanomedicine and advanced technologies for burns: Preventing infection and facilitating wound healing.Targeting the gram-negative bacteria peptidoglycan synthase MraY as a new approach for monoclonal antibody anti-bacterial activity.PscI is a type III secretion needle anchoring protein with in vitro polymerization capacities.An engineered bispecific DNA-encoded IgG antibody protects against Pseudomonas aeruginosa in a pneumonia challenge model.Exoenzyme T Plays a Pivotal Role in the IFN-γ Production after Pseudomonas Challenge in IL-12 Primed Natural Killer Cells.MEDI3902 correlates of protection against severe Pseudomonas aeruginosa pneumonia in a rabbit acute pneumonia model.Conserved OprF as a Selective Immunogen against Pseudomonas aeruginosa.
P2860
Q26768365-696D0DB8-AD02-4F1E-BC82-DB6235BC8A4AQ33822579-D6875449-1E85-4F86-A884-FBD7700FEFCFQ35118409-2FEB13AB-BF5B-4C9C-95BD-CC1C285D6899Q36029891-128746DD-2A24-4995-9C33-18F0C5B97B0DQ36147444-32EB5A59-A138-4017-B072-825151426D14Q36422470-53A4B8D7-33AF-432D-B06A-4C8C2A095797Q36487854-B4260711-E761-4DC9-BC2A-51B323E8F7FCQ36548180-7411ABB4-F27C-44F2-83DB-E88DC196CF71Q36571859-FE9DFCC7-70D9-4385-9EE2-31127A8B8364Q37339442-8403ACBF-61F1-4728-81B8-A08FA99C3839Q38633668-B84D81E7-48B4-4BC7-A3A1-8214E399050DQ38751931-489C6B7A-3F27-4C5E-A0F3-B8E4873FB18BQ38810589-E9C83AA7-EA4D-4664-AE93-40D25B5FC0F7Q38940907-A2730B88-571A-4B32-B5B7-785CB3385D5DQ39173330-282499DB-B1DE-475A-9B1E-5460AADD5E7AQ39197564-0B3EC9C8-4DA8-4A57-B3AA-51FDED50CCAFQ39451464-8E4ACD92-B7DE-4115-8BDA-C2264297AA6BQ40093582-7410709A-9030-4660-A7DD-E21DE010CF4DQ40104332-3B892862-3F80-4875-91AA-EBAA31B02E6AQ40176262-4FBD8B2E-AD4C-4586-8CC6-3FE9A6827B68Q41525965-49CAD640-80E9-45BE-8B06-531F9A800ACBQ41693828-D35DEDD9-0B7F-4A32-ADA6-CB53AA23E2A4Q42700505-95245C03-1534-461A-B98A-9366E68A0432Q51747341-A7536393-5A6E-407D-9D80-C8F2CB9A9D00Q54260241-11072849-9057-4697-AC3B-E31A7572561B
P2860
A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A novel anti-PcrV antibody pro ...... tiple animal infection models.
@ast
A novel anti-PcrV antibody pro ...... tiple animal infection models.
@en
type
label
A novel anti-PcrV antibody pro ...... tiple animal infection models.
@ast
A novel anti-PcrV antibody pro ...... tiple animal infection models.
@en
prefLabel
A novel anti-PcrV antibody pro ...... tiple animal infection models.
@ast
A novel anti-PcrV antibody pro ...... tiple animal infection models.
@en
P2093
P2860
P356
P1476
A novel anti-PcrV antibody pro ...... tiple animal infection models.
@en
P2093
Antonio DiGiandomenico
Bret Sellman
C Kendall Stover
Jessica C Bonnell
Jingying Zha
Kimberly Cook
Maria Camara
Partha Chowdury
Paul Warrener
P2860
P304
P356
10.1128/AAC.02643-14
P407
P577
2014-05-19T00:00:00Z